natgillin/translations-raw huggingface dataset:
Attenuated feline rhinotracheitis herpesvirus (FVH F2 strain): at least 4.9 log 10 CCID50 per dose Inactivated feline Calicivirosis antigens (FCV 431 and FCV G1 strains): at least 2.0 ELISA U per doses Attenuated feline Chlamydophila felis (905 strain): at least 3.0 log 10 EID50 per dose Attenuated feline panleucopenia virus (PLI IV): at least 3.5 log 10 CCID50 per dose FeLV recombinant canarypox virus (vCP97): at least 7.2 log 10 CCID50 per dose
Atenuirani herpes virus rinotraheitisa mačk (sev FHV F2): ≥ 104, 9 CCID50 na odmerek Inaktivirani antigeni kalici virusa mačk (sev FCV 431 in sev FCV G1): ≥ 2, 0 enot v testu ELISA na odmerek Atenuirana Chlamydophila felis (sev 905): ≥ 103, 0 EID50 na odmerek Atenuiran virus panleukopenije mačk (PLI IV): ≥ 103, 5 CCID50 na odmerek Rekombinantni poxvirus kanarčkov, ki vsebuje antigen virusa mačje levkemije (vCP97): ≥ 107, 2 CCID50 na odmerek
Type I glass bottle closed with a butyl elastomer closure and sealed with an aluminium cap
Prebodna steklenička iz stekla tipa 1, zaprta z gumijastim zamaškom in zaščitena z aluminijast o zaporko
EU/ 2/ 04/ 047/ 002
EU/ 2/ 04/ 048/ 002
Attenuated feline rhinotracheitis herpesvirus (FVH F2 strain): at least 4.9 log 10 CCID50 per dose Inactivated feline Calicivirosis antigens (FCV 431 and FCV G1 strains): at least 2.0 ELISA U per doses Attenuated feline Chlamydophila felis (905 strain): at least 3.0 log 10 EID50 per dose Attenuated feline panleucopenia virus (PLI IV): at least 3.5 log 10 CCID50 per dose FeLV recombinant canarypox virus (vCP97): at least 7.2 log 10 CCID50 per dose
Atenuirani herpes virus rinotraheitisa mačk (sev FHV F2): ≥ 104, 9 CCID50 na odmerek Inaktivirani antigeni kalici virusa mačk (sev FCV 431 in sev FCV G1): ≥ 2, 0 enot v testu ELISA na odmerke Atenuirana Chlamydophila felis (sev 905): ≥ 103, 0 EID50 na odmerek Atenuiran virus panleukopenije mačk (PLI IV): ≥ 103, 5 CCID50 na odmerek Rekombinantni poxvirus kanarčkov, ki vsebuje antigen virusa mačje levkemije (vCP97): ≥ 107, 2 CCID50 na odmerek
Attenuated Chlamydophila felis (905 strain).................................................................... ≥ 103.0 EID502 Attenuated feline panleucopenia virus (PLI IV)............................................................ ≥ 103.5 CCID501 Excipient:
Atenuirani herpes virus rinotraheitisa mačk (sev FHV F2)............................................. ≥ 104, 9 CCID501 Inaktivirani antigeni kalici virusa mačk (sev FCV 431 in G1)......................... ≥ 2, 0 enot v testu ELISA Atenuirana Chlamydophila felis (sev 905)......................................................................... ≥ 103, 0 EID502 Atenuiran virus panleukopenije mačk (PLI IV).............................................................. ≥ 103, 5 CCID501 Pomožna snov:
Gentamicin, at most........................................................................................................................ .34 µg Solvent:
34 µg Vehikel:
FeLV recombinant canarypox virus (vCP97)................................................................ ≥ 107.2 CCID501 1: cell culture infective dose 50% 2: egg infective dose 50% For a full list of excipients, see section 6.1.
50% infektivni odmerek za embrionirana kokošja jajca
- against calicivirus infection to reduce clinical signs and excretion,
- Proti okužbam s kalicivirusi, za ublažitev kliničnih znamenj in zmanjšanje izločanje virusov,
- against Chlamydophila felis infection to reduce clinical signs,
- Proti okužbam s Chlamydophila felis, za ublažitev kliničnih znamenj
- against feline panleucopenia to prevent mortality and clinical signs,
- proti mačji panleukopeniji, za preprečevanje smrtnosti in ublažitev kliničnih znamenj,
- against leukaemia to prevent persistent viraemia and clinical signs of the related disease.
- proti leukemiji mačk, za preprečitev perzistentne viremije in ublažitev kliničnih znamenj
Onsets of immunity have been demonstrated 1 week after primary vaccination course for rhinotracheitis, calicivirus, Chlamydophila felis and panleucopenia components, and 2 weeks after primary vaccination course for feline leukaemia component.
Imunost proti levkemiji mačk nastopi2 tedna po osnovnem cepljenju.
The duration of immunity is 1 year after the last (re-)vaccination for rhinotracheitis, calicivirus, Chlamydophila felis and feline leukaemia components, and 3 years for panleucopenia component.
Živali so po zadnjem cepljenju eno leto odporne proti kužnemu rinotraheitisu, okužbam s kalicivirusi, Chlamydophila felis in leukemijo mačk ter tri leta proti mačji panleukopeniji.
4.4 Special warnings
2/ 18 4. 4 Posebna opozorila
It is recommended that a test for FeLV antigenaemia be carried out prior to vaccination.
Pred cepljenjem je priporočljivo opraviti test na prisotnost protiteles proti FeLV.
The reaction was transient.
V zelo redkih primerih sta se en teden do tri tedne po ponovnem cepljenju pri odraslih mačkah pojavili prehodna hipertermija in letargičnost, včasih tudi v povezavi s šepanjem.
Safety and efficacy data are available which demonstrate that this vaccine can be administered the same day but not mixed with Merial adjuvanted vaccine against rabies.
Podatki o varnosti in učinkovitosti dokazujejo, da se lahko cepivo uporabi isti dan kot Merialovo adjuvirano cepivo proti steklini, vendar se ga ne sme mešati z omenjenim cepivom.
Revaccination:
3/ 18 Ponovno cepljenje:
- for all components one year after the primary vaccination course,
- vseh sestavin cepiva eno leto po osnovnem cepljenju
- then every year for the rhinotracheitis, calicivirosis, chlamydiosis and feline leukaemia
- nato enkrat letno ponovimo cepljenje za kužni rinotraheitis, kalicivirus, klamidiozo in
components, and every three years for the panleucopenia component.
Cepljenje proti panleukopeniji ponavljamo vsaka tri leta.
3/ 18 4.10 Overdose (symptoms, emergency procedures, antidotes), if necessary
4. 10 Preveliko odmerjanje (simptomi, nujni ukrepi, protistrupi), če je potrebno
No effect other than those already mentioned in section “ Adverse Reactions”. have been observed, except hyperthermia that may exceptionally last 5 days.
Izjemoma lahko povišana temperatura traja pet dni.
QI06AJ05
Oznaka ATC vet: QI06AJ
The feline leukaemia vaccine strain is a recombinant canarypox virus expressing the env and gag genes of FeLV-A.
Sev virusa v cepivu proti mačji levkemiji je rekombinantni poxvirus kanarčkov, ki izraža env in gag gene FeLV- A.
Under field conditions, only sub-group A is infective and immunisation against sub-group A provides full protection against A, B and C.
Imunizacija proti podskupini A pa omogoča popolno zaščito proti A, B in C.
After inoculation, the virus expresses the protective proteins, but does not replicate in the cat.
Po inokulaciji virus izraža zaščitne proteine, ne da bi se v mački pomnoževal.
4/ 18 6.5 Nature and composition of immediate packaging
4/ 18 6. 5 Vrsta ovojnine in vsebina
5/ 18 ANNEX II
5/ 18 DODATEK II
MANUFACTURER(S) OF THE BIOLOGICAL ACTIVE SUBSTANCE(S) AND MANUFACTURING AUTHORISATION HOLDER(S) RESPONSIBLE FOR BATCH RELEASE
6/ 18 A IZDELOVALEC BIOLOŠKE ZDRAVILNE UČINKOVINE (ZDRAVILNIH UČINKOVIN) IN > IMETNIK DOVOLJENJA ZA IZDELAVO ZDRAVILA, ODGOVOREN ZA SPROSTITEV SERIJE
Merial Laboratory of Lyon Gerland 254, Avenue Marcel Mérieux 69007 LYON France
Merial Laboratory of Lyon Gerland 254, Avenue Marcel Mérieux 69007 LYON Francija
7/ 18 ANNEX III
7/ 18 DODATEK III
9/ 18 PARTICULARS TO APPEAR ON THE OUTER PACKAGE
9/ 18 PODATKI NA ZUNANJI OVOJNINI
11/ 18 MINIMUM PARTICULARS TO APPEAR ON SMALL IMMEDIATE PACKAGING UNITS
11/ 18 PODATKI, KI MORAJO BITI NAJMANJ NAVEDENI NA MANJŠIH STIČNIH OVOJNINAH
Purevax RCPCh FeLV lyophilisate for injection
Purevax RCPCh FeLV liofilizat za injiciranje.
14/ 18 PACKAGE LEAFLET
14/ 18 NAVODILO ZA UPORABO
Purevax RCPCh FeLV Lyophilisate and solvent for suspension for injection.
Purevax RCPCh FeLV Liofilizat in vehikel za suspenzijo za injiciranje
Attenuated Chlamydophila felis (905 strain).................................................................... ≥ 103.0 EID502 Attenuated feline panleucopenia virus (PLI IV)............................................................ ≥ 103.5 CCID501 Excipient:
Atenuirani herpes virus rinotraheitisa mačk (sev FHV F2)............................................. ≥ 104, 9 CCID501 Inaktivirani antigeni kalici virusamačk (seva FCV 431 in G1)........................ ≥ 2, 0 enot v testu ELISA Atenuirana Chlamydophila felis (sev 905)......................................................................... ≥ 103, 0 EID502 Atenuiran virus panleukopenije mačk (PLI IV).............................................................. ≥ 103, 5 CCID501 Pomožna snov:
FeLV recombinant canarypox virus (vCP97)................................................................ ≥ 107.2 CCID501 1: cell culture infective dose 50% 2: egg infective dose 50%
50% infektivni odmerek za embrionirana kokošja jajca
Onsets of immunity have been demonstrated 1 week after primary vaccination course for rhinotracheitis, calicivirus, Chlamydophila felis and panleucopenia components, and 2 weeks after primary vaccination course for feline leukaemia component.
Imunost proti levkemiji mačk nastopi 2 tedna po osnovnem cepljenju.
15/ 18 The duration of immunity is 1 year after the last (re-)vaccination for rhinotracheitis, calicivirus, Chlamydophila felis and feline leukaemia components, and 3 years for panleucopenia component
Živali so po zadnjem cepljenju 1 leto odporne proti kužnemu rinotraheitisu, okužbam s kalicivirusi, Chlamydophila felis in leukemijo mačk ter tri leta proti mačji panleukopeniji.
In the presence of high levels of maternally derived antibodies, the primary vaccination course should be delayed until 12 weeks of age.
V primeru večjih količine maternalnih specifičnih protiteles, je treba osnovno cepljenje začeti pri 12 tednih starosti.
- for all components one year after primary vaccination course,
- eno leto po osnovnem cepljenju
ADVICE ON CORRECT ADMINISTRATION
leukemijo mačk.
Do not mix with any other vaccine or immunological product.
Cepljenje proti panleukopeniji ponavljamo vsaka tri leta.
16/ 18 10.
16/ 18 9.
In case of accidental self-injection, seek medical advice immediately and show the package insert or the label to the physician.
V primeru nenamernega samo- injiciranja se takoj posvetujte z zdravnikom in mu pokažite navodila za uporabo ali nalepko na zunanji ovojnini.
Attenuated Chlamydophila felis (905 strain).................................................................... ≥ 103.0 EID502 Attenuated feline panleucopenia virus (PLI IV)............................................................ ≥ 103.5 CCID501 Excipient:
Atenuirani herpes virus rinotraheitisa mačk (sev FHV F2)............................................  104, 9 CCID 50 1 Inaktivirani antigeni kalici virusa mačk (sev FCV 431 in G1).........................  2, 0 enot v testu ELISA Atenuirana Chlamydophila felis (sev 905)........................................................................  103, 0 EID 50 2 Atenuiran virus panleukopenije mačk (PLI IV).............................................................  103, 5 CCID 50 1 Pomožna snov:
Water for injections.................................................................................................................... q. s.
Voda za injiciranje......................................................................................................................... q. s.
- against feline panleucopenia to prevent mortality and clinical signs.
- proti mačji panleukopeniji, za preprečevanje smrtnosti in ublažitev kliničnih znamenj.
Onsets of immunity have been demonstrated 1 week after primary vaccination course for rhinotracheitis, calicivirus, Chlamydophila felis and panleucopenia components.
Imunost proti kužnemu rinotraheitisu, kalicivirusu mačk, okužbam s Chlamydophila felis in panleukopeniji mačk nastopi 1teden po osnovnem cepljenju.
The duration of immunity is 1 year after the last (re-)vaccination for rhinotracheitis, calicivirus, and Chlamydophila felis, and 3 years for panleucopenia component.
Živali so po zadnjem cepljenju eno leto odporne proti kužnemu rinotraheitisu, okužbam s kalicivirusi in s Chlamydophila felis ter tri leta proti mačji panleukopeniji.
2/ 17 4.5 Special precautions for use
2/ 18 4. 5 Posebni previdnostni ukrepi
Use only in healthy animals
Cepite le zdrave živali.
Safety and efficacy data are available which demonstrate that this vaccine can be mixed with Merial non-adjuvanted vaccine against feline leukaemia and/ or administered the same day but not mixed with Merial adjuvanted vaccine against rabies.
Podatki o varnosti in učinkovitosti dokazujejo, da se lahko cepivo uporablja sočasno z Merialovim neadjuviranim cepivom proti levkemiji mačk in/ ali se ga lahko uporabi isti dan kot Merialovo adjuvirano cepivo proti steklini, vendar se ga ne sme mešati z omenjenim cepivom.
- then every year for the rhinotracheitis, calicivirosis and chlamydiosis components, and
- nato enkrat letno ponovimo cepljenje za kužni rinotraheitis, kalicivirus in klamidiozo
every three years for the panleucopenia component.
Cepljenje proti panleukopeniji ponavljamo vsaka tri leta.
3/ 17 4.10 Overdose (symptoms, emergency procedures, antidotes), if necessary
3/ 18 4. 10 Preveliko odmerjanje (simptomi, nujni ukrepi, protistrupi), če je potrebno
QI06AJ03
Oznaka ATC vet: QI06AJ03
Use immediately after reconstitution.
Uporabite takoj po rekonstituciji
4/ 17 6.6 Special precautions for the disposal of unused veterinary medicinal product or waste materials derived from the use of such products
4/ 18 6. 6 Posebni varnostni ukrepi za odstranjevanje neporabljenega zdravila ali odpadnih snovi
5/ 17 ANNEX II
5/ 18 DODATEK II
MANUFACTURER(S) OF THE BIOLOGICAL ACTIVE SUBSTANCE(S) AND MANUFACTURING AUTHORISATION HOLDER(S) RESPONSIBLE FOR BATCH RELEASE
6/ 18 A IZDELOVALEC BIOLOŠKE ZDRAVILNE UČINKOVINE (ZDRAVILNIH UČINKOVIN) IN IMETNIK DOVOLJENJA ZA IZDELAVO ZDRAVILA, ODGOVOREN ZA SPROSTITEV SERIJE
7/ 17 ANNEX III
7/ 18 DODATEK III
9/ 17 PARTICULARS TO APPEAR ON THE OUTER PACKAGE
9/ 18 PODATKI NA ZUNANJI OVOJNINI
EXP (mm/ yyyy) Use immediately after reconstitution
EXP {mesec/ leto} Uporabite takoj po rekonstituciji.
Store and transport refrigerated (2 °C – 8 °C) protected from light.
Shranjujte in prevažajte pri temperaturi 2C – 8C (v hladilniku).
EU/ 2/ 04/ 050/ 001 Lyophilisate (10 bottles of 1 dose) + solvent (10 bottles of 1 ml) EU/ 2/ 04/ 050/ 002 Lyophilisate (50 bottles of 1 dose) + solvent (50 bottles of 1 ml)
EU/ 2/ 04/ 050/ 001 Liofilizat (10 stekleničk z 1 odmerkom) in vehikel (10 stekleničk po 1 ml) EU/ 2/ 04/ 050/ 002 Liofilizat (50 stekleničk z 1 odmerkom) in vehikel (50 stekleničk po 1 ml)
11/ 17 MINIMUM PARTICULARS TO APPEAR ON SMALL IMMEDIATE PACKAGING UNITS
11/ 18 PODATKI, KI MORAJO BITI NAJMANJ NAVEDENI NA MANJŠIH STIČNIH OVOJNINAH
Purevax RCPCh lyophilisate for injection
Purevax RCPCh liofilizat za injiciranje.
12/ 17 MINIMUM PARTICULARS TO APPEAR ON SMALL IMMEDIATE PACKAGING UNITS
12/ 18 PODATKI, KI MORAJO BITI NAJMANJ NAVEDENI NA MANJŠIH STIČNIH OVOJNINAH
14/ 17 PACKAGE LEAFLET
14/ 18 NAVODILO ZA UPORABO
Purevax RCPCh Lyophilisate and solvent for suspension for injection
Purevax RCPCh Liofilizat in vehikel za suspenzijo za injiciranje
Purevax RCPCh Lyophilisate and solvent for suspension for injection.
Purevax RCPCh Liofilizat in vehikel za suspenzijo za injiciranje
Attenuated Chlamydophila felis (905 strain).................................................................... ≥ 103.0 EID502 Attenuated feline panleucopenia virus (PLI IV)........................................................... ≥ 103.5 CCID501 Excipient:
Atenuirani herpes virus rinotraheitisa mačk (sev FHV F2)............................................  104, 9 CCID 50 1 Inaktivirani antigeni kalici virusamačk (seva FCV 431 in G1)........................  2, 0 enot v testu ELISA Atenuirana Chlamydophila felis (sev 905)........................................................................  103, 0 EID 50 2 Atenuiran virus panleukopenije mačk (PLI IV).............................................................  103, 5 CCID 50 1 Pomožna snov:
- against chlamydophila felis infection to reduce clinical signs,
- Proti okužbam s Chlamydophila felis, za ublažitev kliničnih znamenj
15/ 17 The duration of immunity is 1 year after the last (re-)vaccination for rhinotracheitis, calicivirus, and Chlamydophila felis, and 3 years for panleucopenia component.
Živali so po zadnjem cepljenju1 leto odporne proti kužnemu rinotraheitisu, okužbam s kalicivirusi in s Chlamydophila felis ter tri leta proti mačji panleukopeniji.
every three years for the panleucopenia component.
- nato enkrat letno ponovimo cepljenje za kužni rinotraheitis, kalicivirus in klamidiozo.
Use immediately after reconstitution.
Cepljenje proti panleukopeniji ponavljamo vsaka tri leta.
EPAR summary for the public This document is a summary of the European Public Assessment Report.
Povzetek EPAR za javnost Ta dokument je povzetek evropskega javnega poročila o oceni zdravila (EPAR).
Purevax RCP FeLV is a vaccine containing the following active substances: • attenuated (weakened) feline rhinotracheitis herpesvirus (FHV F2 strain), • inactivated (killed) calicivirosis antigens (FCV 431 and G1 strains), • attenuated feline panleucopenia virus (PLI IV), • feline leukaemia virus (FeLV) recombinant canarypox virus (vCP97).
Zdravilo Purevax RCP FeLV je cepivo, ki vsebuje naslednje zdravilne učinkovine: • atenuirani (oslabljeni) herpesvirus rinotraheitisa mačk (sev FHV F2), • inaktivirane (uničene) antigene kalicivirusa (sev FCV 431 in G1), • atenuirani virus panleukopenije mačk (PLI IV), • rekombinantni poxvirus kanarčkov (vCP97), ki vsebuje antigen virusa mačje levkemije (FeLV).
Purevax RCP FeLV is used to vaccinate cats from the age of 8 weeks against the following diseases: • feline viral rhinotracheitis (a flu-like illness caused by a herpesvirus), • feline calicivirosis (a flu-like illness with inflammation of the mouth caused by a calicivirus), • feline panleucopenia (a serious illness causing bloody diarrhoea caused by a parvovirus), • feline leukaemia (an illness affecting the immune system caused by a retrovirus).
Zdravilo Purevax RCP FeLV se uporablja za cepljenje mačk od 8. tedna starosti naprej proti naslednjim boleznim: • virusnemu rinotraheitisu mačk (gripi podobni bolezni, ki jo povzroča herpesvirus), • kalicivirozi mačk (gripi podobni bolezni z vnetjem ust, ki jo povzroča kalicivirus), • panleukopeniji mačk (resni bolezni, ki povzroča krvavo drisko in jo povzroča parvovirus), • mačji levkemiji (bolezni, ki prizadene imunski sistem in jo povzroča retrovirus).
(44-20) 74 18 84 00 Fax (44-20) 74 18 84 16 E-mail: mail@emea. europa. eu http: / /www. emea. europa. eu ©EMEA 2008 Reproduction and/ or distribution of this document is authorised provided the source is acknowledged How does Purevax RCP FeLV work?
(44- 20) 74 18 84 00 Fax (44- 20) 74 18 84 16 E- mail: mail@ emea. europa. eu http: // www. emea. europa. eu ©EMEA 2008 Reproduction and/ or distribution of this document is authorised provided the source is acknowledged Kako zdravilo Purevax RCP FeLV deluje?
Purevax RCP FeLV contains small amounts of weakened or killed viruses that cause the diseases listed above, as well as two genes from the FeLV called env and gag, which have been inserted into another vector (carrier) virus called canarypox using ‘ recombinant DNA technology’.
Zdravilo Purevax RCP FeLV vsebuje majhne količine oslabljenih ali uničenih virusov, ki povzročajo zgoraj navedene bolezni, ter dva gena virusa FeLV, imenovana env in gag, ki so ju s „ tehnologijo rekombinantne DNA “ vstavili v drug virusni (prenašalni) vektor, imenovan poxvirus kanarčkov.
When a cat is given the vaccine, the immune system recognises the weakened or killed viruses and the FeLV proteins as ‘ foreign’ and makes antibodies against them.
Ko mačko cepimo, imunski sistem prepozna oslabljene ali uničene viruse in beljakovine virusa FeLV kot „ tuje “ ter proti njim razvije protitelesa.
In the field the studies of Purevax RCP FeLV looked at the basic vaccination schedule (2 injections 3-4 weeks apart) and at the booster vaccination (only one injection).
V študijah zdravila Purevax RCP FeLV na terenu so preučevale osnovno shemo cepljenja (2 injekciji 3– 4 tedne narazen) ter obnovitveno cepljenje (samo ena injekcija).
The Committee for Medicinal Products for Veterinary Use (CVMP) concluded that the benefits of Purevax RCP FeLV exceed the risks for the active immunisation of cats aged eight weeks or older against the diseases listed above, and recommended that Purevax RCP FeLV be given a marketing authorisation.
Zato je priporočil, da se za zdravilo Purevax RCP FeLV odobri dovoljenje za promet.
Attenuated feline Rhinotracheitis herpesvirus (FVH F2 strain): at least 4.9 log 10 CCID50 per dose Inactivated feline Calicivirosis antigens (FCV 431 and FCV G1 strains): at least 2.0 ELISA U per dose Attenuated feline Panleucopenia virus (PLI IV): at least 3.5 log 10 CCID50 per dose FeLV recombinant canarypox virus (vCP97): at least 7.2 log 10 CCID50 per dose
Atenuirani herpes virus rinotraheitisa mačk (sev FHV F2): ≥ 104, 9 CCID50 na odmerek Inaktivirani antigeni kalici virusa mačk (sev FCV 431 in sev FCV G1): ≥ 2, 0 enot v testu ELISA na odmerek Atenuiran virus panleukopenije mačk (PLI IV): ≥ 103, 5 CCID50 na odmerek Rekombinantni poxvirus kanarčkov, ki vsebuje antigen virusa mačje levkemije (vCP97): ≥ 107, 2 CCID50 na odmerek
Lyophilisate and Cats solvent for suspension for injection
Liofilizat in vehikel za suspenzijo za injiciranje
Attenuated feline panleucopenia virus (PLI IV)............................................................  103.5 CCID 50 1 Excipient:
Atenuirani herpes virus rinotraheitisa mačk (sev FHV F2)............................................  104, 9 CCID 50 1 Inaktivirani antigeni kalici virusa mačk (sev FCV 431 in G1).........................  2, 0 enot v testu ELISA Atenuiran virus panleukopenije mačk (PLI IV).............................................................  103, 5 CCID 50 1 Pomožna snov:
23 µg Solvent:
23 µg Vehikel:
FeLV recombinant canarypox virus (vCP97)................................................................  10 7.2 CCID 50 1 1: cell culture infective dose 50% For a full list of excipients, see section 6.1.
50% infektivni odmerek za celično kulturo
Onsets of immunity have been demonstrated 1 week after primary vaccination course for rhinotracheitis, calicivirus and panleucopenia components, and 2 weeks after primary vaccination course for feline leukaemia component.
Imunost proti levkemiji mačk nastopi 2 tedna po osnovnem cepljenju.
The duration of immunity is 1 year after the last (re-)vaccination for rhinotracheitis, calicivirus and feline leukaemia components, and 3 years for panleucopenia component.
Živali so po zadnjem cepljenju eno leto odporne proti kužnemu rinotraheitisu, okužbam s kalicivirusi in leukemiji mačk ter tri leta proti mačji panleukopeniji.
In normal condition of use, transient apathy and anorexia may occasionally occur, as well as hyperthermia (lasting usually for 1 or 2 days).
Lahko se pojavi tudi povišana telesna temperatura (običajno traja 1 do 2 dni).
Safety and efficacy data are available which demonstrate that this vaccine can be administered the same day but not mixed with Merial adjuvanted vaccine against rabies.
Podatki o varnosti in učinkovitosti dokazujejo, da se lahko cepivo uporablja isti dan kot Merialovo adjuvirano cepivo proti steklini, vendar se ga ne sme mešati z omenjenim cepivom.
Inject by subcutaneous route one 1 ml dose of vaccine after reconstitution of the lyophilisate with the solvent, according to the following vaccination scheme:
Po rekonstituciji liofilizirane sestavine z vehiklom injicirajte 1 ml odmerek cepiva v podkožje, po naslednjem razporedu:
- then every year for the rhinotracheitis, calicivirosis and feline leukaemia components, and every
- nato enkrat letno ponovimo cepljenje za kužni rinotraheitis, kalicivirus in leukemijo mačk.
three years for the panleucopenia component.
Cepljenje proti panleukopeniji ponavljamo vsaka tri leta.
QI06AH
Oznaka ATC vet: QI06AH